Other Events ·
Prime Medicine, Inc. received a final arbitration award on July 6, 2026, ruling that its PM647 candidate for Alpha-1…
PRMEPrime Medicine, Inc.
Prime Medicine, Inc. received a final arbitration award on July 6, 2026, ruling that its PM647 candidate for Alpha-1 Antitrypsin Deficiency treatment is within its defined field of use, meaning the company did not breach its 2019 Collaboration and License Agreement with Beam Therapeutics, Inc. The Tribunal denied all requests for damages and injunctive relief from Beam. Prime Medicine, Inc. is a biotechnology company focused on on-target genome editing.</u>